Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Immunic

DB:10VA
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
10VA
DB
$65M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Immunic has significant price volatility in the past 3 months.
10VA Share Price and Events
7 Day Returns
7.8%
DB:10VA
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:10VA
-7.4%
DE Biotechs
-14.2%
DE Market
10VA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Immunic (10VA) 7.8% -24.7% -31.7% - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on 10VA.
  • No trading data on 10VA.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

10VA Value

 Is Immunic undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Immunic. This is due to cash flow or dividend data being unavailable. The share price is €5.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Immunic's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Immunic's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:10VA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-4.52
NasdaqCM:IMUX Share Price ** NasdaqCM (2020-04-08) in USD $6.09
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Immunic.

DB:10VA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:IMUX Share Price ÷ EPS (both in USD)

= 6.09 ÷ -4.52

-1.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunic is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Immunic is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Immunic's expected growth come at a high price?
Raw Data
DB:10VA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
41.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Immunic, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Immunic's assets?
Raw Data
DB:10VA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.43
NasdaqCM:IMUX Share Price * NasdaqCM (2020-04-08) in USD $6.09
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:10VA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:IMUX Share Price ÷ Book Value per Share (both in USD)

= 6.09 ÷ 5.43

1.12x

* Primary Listing of Immunic.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunic is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Immunic's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Immunic has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

10VA Future Performance

 How is Immunic expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Immunic expected to grow at an attractive rate?
  • Immunic's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Immunic's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Immunic's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:10VA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:10VA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 41.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:10VA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:10VA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 234 138 1
2023-12-31 64 -22 1
2022-12-31 0 -79 2
2021-12-31 0 -61 2
2020-12-31 0 -46 2
2020-04-09
DB:10VA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -29 -35
2019-09-30 -26 -32
2019-06-30 -22 -26
2019-03-31 -13 -14
2018-12-31 -10 -12
2018-09-30 -10 -10
2017-12-31 -10 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Immunic's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Immunic is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:10VA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Immunic Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:10VA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 6.96 6.96 6.96 1.00
2023-12-31 -1.15 -1.15 -1.15 1.00
2022-12-31 -4.49 -4.49 -4.49 1.00
2021-12-31 -4.55 -4.55 -4.55 1.00
2020-12-31 -3.59 -3.59 -3.59 1.00
2020-04-09
DB:10VA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -4.52
2019-09-30 -7.01
2019-06-30 -11.30
2019-03-31 -271.84
2018-12-31 -13.63
2018-09-30 -16.79
2017-12-31 -199.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Immunic will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Immunic's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Immunic has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

10VA Past Performance

  How has Immunic performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Immunic's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Immunic does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Immunic's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Immunic's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Immunic's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Immunic Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:10VA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -34.93 14.52 22.51
2019-09-30 -32.05 5.25 20.73
2019-06-30 -25.64 3.57 15.04
2019-03-31 -13.59 3.20 11.17
2018-12-31 -11.54 2.40 9.60
2018-09-30 -10.17 1.92 8.51
2017-12-31 -9.96 1.25 8.75
2016-12-31 0.01 -1.38 0.53 0.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Immunic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Immunic has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Immunic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Immunic's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Immunic has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

10VA Health

 How is Immunic's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Immunic's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Immunic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Immunic's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Immunic's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Immunic has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Immunic Company Filings, last reported 3 months ago.

DB:10VA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 58.36 0.00 29.37
2019-09-30 60.53 0.00 30.46
2019-06-30 69.41 0.00 36.12
2019-03-31 27.42 0.00 7.59
2018-12-31 11.45 0.00 13.07
2018-09-30 12.62 0.00 10.03
2017-12-31 4.60 0.00 4.50
2016-12-31 8.05 0.00 5.67
  • Immunic has no debt.
  • Immunic has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Immunic has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Immunic has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Immunic's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Immunic has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

10VA Dividends

 What is Immunic's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Immunic dividends.
If you bought €2,000 of Immunic shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Immunic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Immunic's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:10VA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:10VA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Immunic has not reported any payouts.
  • Unable to verify if Immunic's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Immunic's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Immunic has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Immunic's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Immunic afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Immunic has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

10VA Management

 What is the CEO of Immunic's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Daniel Vitt
AGE 51
TENURE AS CEO 3.3 years
CEO Bio

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic AG since January 1, 2017 and also its President. Dr. Vitt served as Managing Director of 4SC Discovery GmbH. Dr. Vitt Co-founded 4SC AG in November 1997 and served as its Member of Management Board at 4SC AG from 2000 to December 31, 2016. Dr. Vitt served as the Chief Development Officer and Chief Scientific Officer at 4SC AG until December 31, 2016. He has been the pioneer behind 4SC's VHTS method providing the key components of 4SC AG's innovative technology platform. He serves as a Director of Immunic AG and Nexigen GmbH. During his doctoral work, he contributed to the development of new active substances against tropical diseases. He completed a Masters degree and a Doctorate at the Institute of Organic Chemistry, University of Würzburg (Germany) in 1998.

CEO Compensation
  • Insufficient data for Daniel to compare compensation growth.
  • Insufficient data for Daniel to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the Immunic management team in years:

3.3
Average Tenure
  • The tenure for the Immunic management team is about average.
Management Team

Daniel Vitt

TITLE
CEO, President & Director
AGE
51
TENURE
3.3 yrs

Manfred Gröppel

TITLE
Co-Founder & COO

Andreas Mühler

TITLE
Co-Founder and Chief Medical Officer
AGE
56

Sanjay Patel

TITLE
Chief Financial Officer
TENURE
0.8 yrs

Hella Kohlhof

TITLE
Chief Scientific Officer
TENURE
3.3 yrs

Jessica Breu

TITLE
Manager of IR & Communications
Board of Directors Tenure

Average tenure and age of the Immunic board of directors in years:

2.3
Average Tenure
51.5
Average Age
  • The average tenure for the Immunic board of directors is less than 3 years, this suggests a new board.
Board of Directors

Duane Nash

TITLE
Chairman
AGE
48
TENURE
1.3 yrs

Daniel Vitt

TITLE
CEO, President & Director
AGE
51

Vincent Ossipow

TITLE
Director
AGE
51
TENURE
3.3 yrs

Tamar Howson

TITLE
Director
AGE
70
TENURE
0.5 yrs

Buck Phillips

TITLE
Director
AGE
56
TENURE
0.4 yrs

Joerg Neermann

TITLE
AGE
52
TENURE
4.3 yrs

Jan Van den Bossche

TITLE
Director
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Immunic's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Immunic has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

10VA News

Simply Wall St News

10VA Company Info

Description

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.

Details
Name: Immunic, Inc.
10VA
Exchange: DB
Founded:
$60,174,824
10,744,806
Website: http://www.immunic-therapeutics.com
Address: Immunic, Inc.
11440 West Bernardo Court,
Suite 300,
San Diego,
California, 92127,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM IMUX Common Stock Nasdaq Capital Market US USD 15. Apr 2019
DB 10VA Common Stock Deutsche Boerse AG DE EUR 15. Apr 2019
Number of employees
Current staff
Staff numbers
26
Immunic employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 02:02
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.